George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Nice one, thanks for all the links, great research and very interesting to see what the competition is up to. I think it's worth noting that these treatments are pretty revolutionary, so any advancements in the respective fields should be seen as positive validation for the treatment mechanisms in general.
Another link below that people may find informative; I really do think exosomes based treatments and diagnostics are going to be huge within the next 5 years and beyond. Great space for the company to be involved in.
https://www.youtube.com/watch?v=4MeVPYAz7Xc&ab_channel=Lonza
There could be three major bits of news this month potentially.
With reference to the published timeline from the January analyst presentation, the company expects the last of the expanded phase 2a cohort to be treated in Q2 2021. I'm not totally convinced this will be achieved, but we are aware from the LinkedIn post the other week that the Barcelona trial site is now recruiting. Other info on the clinical trails site hasn't been updated since start of March, but you would hope good progress is being made elsewhere too.
The other anticipated event from the timeline is POC data 'for delivery of functional proteins by CTX derived exosomes'. This obviously could be a huge moment for the company if the anticipated data are forthcoming, with outlicensing deals almost inevitable at that juncture.
Finally, from the 12th March RNS, Michael Hunt will be serving his notice until the end of May as CFO. We can therefore assume an announcement will be made on his successor in the coming weeks.
I wonder if its any coincidence that a new CFO is being brought in just as the company is expected to be negotiating potentially transformational collaboration deals on the back of POC exosome data? Looking forward to seeing how it plays out.
I'm struggling to see how people could have expected any more from this trial. Surely just about the best outcome we could have anticipated, given the nature of the disease and the setting. Anyway, will be interesting to hear them provide some commentary at 9am.
https://www.bbc.co.uk/news/health-56906002
Great to hear how this has helped change people's lives. Hopefully one day we'll be reading similar stories about people benefiting from treatments developed by Reneuron.
Certainly a detailed note, and interesting to get further insight especially on some of the less well publicised deals across the market.
What I have also noticed in the last 6 months or so is an increasing number of references to the iPSC programme. I don't fully understand what the potential is here, and also don't really know of the competition. However, I'm presuming it's possible for others to licence the company's iPSC programme in the future as a means of creating and manufacturing whatever cell they want for their own studies. If so (and obviously I freely admit I am speculating), then it perhaps means this side of the business could develop in a similar way to the Maxcyte business model for gene therapy.
Development stage companies paying Rene to use their technology to develop cell therapies, then milestone payments, followed by royalties if the treatments get to market. Almost no risk to Rene, with income streams from a range of potential partners and value getting baked in as the other companies advance their studies. Massive potential if that's the case. Any thoughts welcome on that point, as perhaps I'm barking up the wrong tree, but seems possible.
I think the technicals are looking pretty rosy right now and this brings confident and bullish investors/traders to the table. Been having a look at the charts on tradingview and assuming there isn't some spectacular crash before the end of this month (probably shouldn't have said that), we will have had 4 consecutive green months, which included a breakout in January from long term resistance and a bear market.
The monthly MACD is now extremely close to a bullish crossover, and that is one of the most powerful signals for medium to long term bullish sentiment you can look for in technical analysis. No such thing as a certainty with any of this as you will all well know, but the fundamentals and technicals are aligning nicely for the months ahead.
Hopefully it finally bears fruit.
A mention in the Investors Chronicle may have given it a tail wind today:
https://www.investorschronicle.co.uk/ideas/2021/04/21/reneuron-refinanced-and-ready-to-rise/
https://www.linkedin.com/posts/reneuron_stemcells-retinitispigmentosa-collaborativework-activity-6790550816093724673-tIEf
For those that don't have LinkedIn, this is Rene sharing a post from Jordi Mones at Barcelona Macula Foundation:
"Very excited to be sharing this news at ReNeuron Group Plc.
https://lnkd.in/esMrezN
#stemcells #retinitispigmentosa"
And the original post from Jordi below. . . . . . .
"First time trial of retinal #stemcells in #retinitispigmentosa in Europe. Very excited to share the approval by the EU and Spanish authorities for the First-in-human clinical trial Phase I/IIa of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Subjects with Retinitis Pigmentosa (RP) at Institut de la Màcula in Barcelona, working with ReNeuron Group Plc. Very grateful of the huge #collaborativework done by both entities, by the preceding and current investigators in US, as well by the CRO Ora, Inc. to make possible the starting of this journey to contribute to battle blindness. Now recruiting and selecting the appropriate candidates.
https://lnkd.in/dbvR2jJ
#blindness #stemcelltherapy #retina #raredisease #research #scientists #clinicalresearch #regenerativemedicine #science #innovationinhealthcare #opthalmology"
I'm trying to think back to last year when they managed to release a really positive RNS (maybe about exosome collab or something else generally very good) on the same day that the WHO announced that covid was a global pandemic. Price went up about 10% early doors and then finished the day either flat or down. Classic.
Hopefully the false dawns are now behind us, but you never know.
Agree Grizzly. Exopharm’s main claim is that they can scale exosomes to a commercial level, whilst suggesting that the likes of codiak and evox haven't yet been able to demonstrate this. From my understanding, rene is capable of this due to all the work that has gone in to CTX over the years.
Clinical grade and fully scalable are the words management use, I think.
Without being an expert in the field it's obviously difficult to say with certainty, but it does seem like we might be a little behind in terms of the exosome programme compared to evox and codiak, but I do think the huge amount of time and money spent on developing CTX may infer certain benefits for our exosome programme in the future.
'ReNeuron
Former City broker Richard Griffiths has been dubbed the ‘Welsh Wizard’ for his stock market bets, and has brought plenty of fellow investors under his spell.
So market watchers take note. It has emerged that the Jersey dweller has taken a 7 per cent stake in ReNeuron.
The small-cap is a stem cell research specialist which recently raised £15 million to expand a study of its treatment for a degenerative eye disease.
The shares have rallied over the last month, up more than 30 per cent at £1.33. Griffiths’ followers will have their eyes trained on this one.'
https://www.thisismoney.co.uk/money/markets/article-9457285/STOCK-WATCH-whos-favourite-William-Hill-takeover.html
One particular company notable by its absence here. Hopefully the next few months makes this look very out of date....
https://www.labiotech.eu/trends-news/exosome-evox-therapeutics/
Couple of quick points to pick out from that Olav interview. Q2 they will treat the remaining 6 patients from the expanded phase 2a hrpc trial, with 3 month readout from all patients in Q3.
With regards to the latest slides, these also highlight that further POC data from exosomes preclinical studies is expected in H1.
So, in the next 3 months we should be expecting announcements for hrpc, exosomes, and also details regarding the new incoming cfo. A steady bit of news flow to be looking forward to.
Very true, Surprised2, however the valuations that Edison and Stifel reach will be based on projected future sales, adjusted for risk/probability of success.
As the risk reduces (hopefully) and the products get closer to market, then there will be substantial head room for those valuations to increase. The main derisking event will of course be continued positive data from the expanded phase 2a hrpc trial.
Not sure what value is being implied for the exosomes programme in the Stifel research, but from memory I don't think Edison actually gave any proper value to it as its preclinical, but at least did start acknowledging the high level of industry interest and also the value of some of the deals being done in that space. Speaking of Edison, was their last update the end of January? They seem to update their research every quarter or so, so perhaps we can expect a new note from them soon.
It turns out Reneuron started a twitter account in the last few days. Surprised they've waited this long, but hopefully further indication of the intention to get the company recognised and engaged with investors in the future. Their first tweet is much in line with the tweet I shared from Walbrook yesterday...
'Stifel reiterates its BUY recommendation for #RENE in the latest research, stating that ReNeuron offers the ‘greatest potential upside within its UK healthcare coverage’ and is a 'fundamentally mispriced stock at current levels'. Target price of 400p.
#StemCell #Exosomes #CTX'
Again, if anyone has access to the Stifel research it would be great to get some insight, as the above snippet is rather a bold claim, but obviously welcome to hear.
'Stifel reiterates BUY rating for ReNeuron @ReNeuronPLC #RENE - offering the greatest potential upside within Stifel’s UK healthcare coverage, Stifel see the current share price as an attractive entry point ahead of major value inflection points in 2021. Target Price of 400p'
https://twitter.com/WalbrookPR/status/1377210957303271424?s=19
Anyone happen to have access to the Stifel report?
The value disconnect just amazes me. The ProQR results for phase 1/2, showing a mean benefit from treated to untreated eye of +6 letters average across 14 patients, put approximately $180m on their MCAP, when announced. That's for a gene therapy that treats a small subset of RP mutations.
Reneuron, from their latest published read-out at 12 months, across 7 patients, show a mean improvement of approximately +12 letters between treated and untreated eyes. For a treatment that is non gene dependent, so can potentially treat the entire RP population. And yet we're sat here with a MCAP of around £60m, and an enterprise value of around £40m.
Get this company on the NASDAQ as a matter of priority, the UK market simply does not understand the potential here.
Bit depressing watching the share price sink back after the fantastic RNS a week ago, really did expect it to kick on with the level of value clearly now being baked into the various platforms.
Anyway, by means of a comparison, results were released by ProQR therapeutics the other day, see below.
https://www.proqr.com/press-releases/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials
ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
Across all treated patients (n=14), a mean benefit of 6.0 letters was observed at week 48 in the treated eyes compared to the untreated (contralateral) eyes after a single injection.
Share price up around 60% after releasing the results. MCAP of over $400m.
They have one study in phase 1, one study in phase 1/2, and another in phase 2/3.
I think it shows just how close Reneuron are to realising its true value at long last. Further positive data from the expanded phase 2a study and we will be moving in a pivotal phase 3 study. At which point the value disconnect from Reneuron and its peers will simply have to be acknowledged by the market. Upfront payments for any licencing deals for a phase 3 candidate will eclipse the current MCAP. The same is likely true for any exosomes deals that will be taken into clinical study.